Meeting NewsPerspective

Pembrolizumab plus chemotherapy prolongs OS, PFS for metastatic lung cancer

October 1, 2018
The addition of pembrolizumab to chemotherapy extended OS and PFS compared with chemotherapy alone among patients with metastatic, squamous…
Meeting News

Women with lung cancer live longer than men

October 1, 2018
Women with newly diagnosed stage I to stage III non-small cell lung cancer appeared to have longer OS than their male counterparts, according to…
Meeting NewsPerspective

Durvalumab extends OS in advanced lung cancer

September 28, 2018
Durvalumab prolonged OS among patients with locally advanced, unresectable stage III non-small cell lung cancer that did not progress following…
Meeting News

Atezolizumab plus chemotherapy improves small cell lung cancer survival

September 28, 2018
The addition of frontline atezolizumab to carboplatin plus etoposide improved OS and PFS among patients with extensive-stage small cell lung cancer…
Meeting News

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer

September 27, 2018
First-line therapy with brigatinib significantly improved PFS compared with crizotinib among treatment-naive patients with advanced ALK-positive…
Meeting News

LOXO-292 safe, effective for RET-altered non-small cell lung cancer

September 27, 2018
LOXO-292 appeared well tolerated and demonstrated antitumor activity among patients with heavily pretreated RET fusion-positive non-small cell lung…
Meeting News

First-line atezolizumab plus chemotherapy improves PFS for lung cancer

September 25, 2018
The addition of frontline atezolizumab to carboplatin or cisplatin plus pemetrexed improved PFS among patients with non-small cell lung cancer…
Meeting News

Entrectinib safe, effective for ROS1-positive non-small cell lung cancer

September 25, 2018
Entrectinib shrank tumors among patients with ROS1-positive non-small cell lung cancer and generally was well tolerated, according to results from…